Shattuck Labs, Inc. Operating Expenses
Shattuck Labs, Inc. (STTK) reported Operating Expenses of $16.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- Shattuck Labs, Inc. operating expenses for the quarter ending 2026-06-30 was $16.16M, a 23.96% increase year-over-year.
- Shattuck Labs, Inc. operating expenses for the quarter ending 2026-03-31 was $15.54M, a 8.03% increase year-over-year.
- Shattuck Labs, Inc. operating expenses for the quarter ending 2025-12-31 was $13.37M, a 31.92% decline year-over-year.
- Shattuck Labs, Inc. operating expenses for the quarter ending 2025-09-30 was $11.72M, a 43.99% decline year-over-year.
- Shattuck Labs, Inc. operating expenses for fiscal 2025 was $52.51M, a 39.15% decline from fiscal 2024.
- Shattuck Labs, Inc. operating expenses for fiscal 2024 was $86.29M, a 7.83% decline from fiscal 2023.
- Shattuck Labs, Inc. operating expenses for fiscal 2023 was $93.61M, a 9.97% decline from fiscal 2022.
- Shattuck Labs, Inc. operating expenses for fiscal 2022 was $103.98M, a 38.11% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.16M 10-Q · filed 2026-08-11 | $31.70M 10-Q · filed 2026-08-11 | $45.07M derived: sum of 3 quarters · filed 2026-08-11 | $56.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $15.54M 10-Q · filed 2026-05-07 | $28.92M derived: sum of 2 quarters · filed 2026-05-07 | $40.63M derived: sum of 3 quarters · filed 2026-05-07 | $53.66M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $13.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $25.09M derived: sum of 2 quarters · filed 2026-03-05 | $38.12M derived: sum of 3 quarters · filed 2026-08-11 | $52.51M 10-K · filed 2026-03-05 |
| 2025-09-30 | $11.72M 10-Q · filed 2025-11-06 | $24.75M derived: sum of 2 quarters · filed 2026-08-11 | $39.14M 10-Q · filed 2025-11-06 | $58.78M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $13.03M 10-Q · filed 2026-08-11 | $27.42M 10-Q · filed 2026-08-11 | $47.06M derived: sum of 3 quarters · filed 2026-08-11 | $67.98M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $14.39M 10-Q · filed 2026-05-07 | $34.03M derived: sum of 2 quarters · filed 2026-05-07 | $54.95M derived: sum of 3 quarters · filed 2026-05-07 | $79.52M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $19.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $40.56M derived: sum of 2 quarters · filed 2026-03-05 | $65.13M derived: sum of 3 quarters · filed 2026-03-05 | $86.29M 10-K · filed 2026-03-05 |
| 2024-09-30 | $20.92M 10-Q · filed 2025-11-06 | $45.49M derived: sum of 2 quarters · filed 2025-11-06 | $66.65M 10-Q · filed 2025-11-06 | $86.31M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $24.57M 10-Q · filed 2025-08-14 | $45.73M 10-Q · filed 2025-08-14 | $65.39M derived: sum of 3 quarters · filed 2025-08-14 | $94.68M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $21.16M 10-Q · filed 2025-05-01 | $40.82M derived: sum of 2 quarters · filed 2025-05-01 | $70.11M derived: sum of 3 quarters · filed 2025-05-01 | $93.06M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $19.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $48.95M derived: sum of 2 quarters · filed 2025-03-27 | $71.90M derived: sum of 3 quarters · filed 2025-03-27 | $93.61M 10-K · filed 2025-03-27 |
| 2023-09-30 | $29.28M 10-Q · filed 2024-11-14 | $52.23M derived: sum of 2 quarters · filed 2024-11-14 | $73.95M 10-Q · filed 2024-11-14 | $100.61M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $22.95M 10-Q · filed 2024-08-01 | $44.66M 10-Q · filed 2024-08-01 | $71.33M derived: sum of 3 quarters · filed 2024-08-01 | $96.77M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $21.72M 10-Q · filed 2024-05-02 | $48.38M derived: sum of 2 quarters · filed 2024-05-02 | $73.83M derived: sum of 3 quarters · filed 2024-05-02 | $101.53M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $26.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $52.11M derived: sum of 2 quarters · filed 2024-02-29 | $79.81M derived: sum of 3 quarters · filed 2024-02-29 | $103.98M 10-K · filed 2024-02-29 |
| 2022-09-30 | $25.44M 10-Q · filed 2023-11-09 | $53.15M derived: sum of 2 quarters · filed 2023-11-09 | $77.31M 10-Q · filed 2023-11-09 | $98.15M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $27.71M 10-Q · filed 2023-08-10 | $51.87M 10-Q · filed 2023-08-10 | $72.71M derived: sum of 3 quarters · filed 2023-08-10 | $92.19M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $24.17M 10-Q · filed 2023-05-09 | $45.00M derived: sum of 2 quarters · filed 2023-05-09 | $64.48M derived: sum of 3 quarters · filed 2023-05-09 | $84.76M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $20.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $40.31M derived: sum of 2 quarters · filed 2023-02-23 | $60.59M derived: sum of 3 quarters · filed 2023-02-23 | $75.29M 10-K · filed 2023-02-23 |
| 2021-09-30 | $19.48M 10-Q · filed 2022-11-09 | $39.76M derived: sum of 2 quarters · filed 2022-11-09 | $54.45M 10-Q · filed 2022-11-09 | $67.81M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $20.28M 10-Q · filed 2022-08-11 | $34.97M 10-Q · filed 2022-08-11 | $48.33M derived: sum of 3 quarters · filed 2022-08-11 | $62.60M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $14.69M 10-Q · filed 2022-05-12 | $28.05M derived: sum of 2 quarters · filed 2022-05-12 | $42.32M derived: sum of 3 quarters · filed 2022-05-12 | $51.82M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $13.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $27.63M derived: sum of 2 quarters · filed 2022-03-15 | $37.13M derived: sum of 3 quarters · filed 2022-03-15 | $46.87M 10-K · filed 2022-03-15 |
| 2020-09-30 | $14.27M 10-Q · filed 2021-11-09 | $23.77M derived: sum of 2 quarters · filed 2021-11-09 | $33.51M 10-Q · filed 2021-11-09 | $43.96M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $9.50M 10-Q · filed 2021-08-12 | $19.24M 10-Q · filed 2021-08-12 | $29.68M derived: sum of 3 quarters · filed 2021-08-12 | $38.99M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $9.74M 10-Q · filed 2021-05-10 | $20.18M derived: sum of 2 quarters · filed 2021-05-10 | $29.49M derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | $10.45M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $19.76M derived: sum of 2 quarters · filed 2021-03-16 | $34.95M 10-K · filed 2021-03-16 | |
| 2019-09-30 | $9.31M 10-Q · filed 2020-11-13 | $24.51M 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |